Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,007,065

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Arpita Dutt headshot

Forget Gilead, Buy These 5 Biotech Stocks Instead

With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.

    Sweta Killa headshot

    Biotech ETFs Powered by Q4 Earnings

    Improved earnings are driving the biotech space and ETFs higher over the past 10 days.

      Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints

      Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.

        Arpita Dutt headshot

        Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

        Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

          Tracey Ryniec headshot

          Healthcare Stocks: The Buying Opportunity of the Year?

          Tracey and Kevin discuss whether healthcare stocks are still the ???sure things??? they???ve been the last 10 years.

            Madeleine Johnson headshot

            Gilead Sciences Posts Q4 Earnings Beat, Slumps on Weak Guidance

            Gilead Sciences Inc. (GILD) just released its fourth quarter fiscal 2016 financial results, posting earnings, before non-recurring items, of $2.64 cents per share and revenues of $7.3 billion

              Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?

              Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.

                Arpita Dutt headshot

                Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline

                2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review

                  There were quite a few updates on the regulatory front this week in the biotech sector including FDA approval for Synergy's (SGYP) drug.

                    Gilead (GILD) HCV Therapy Application Validated in Europe

                    Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated.

                      Is Gilead Sciences (GILD) a Great Stock for Value Investors?

                      Let's delve into the value metrics of Gilead Sciences (GILD) and determine whether it is a good value investment right now.

                        The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin

                        The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin

                          4 Top Biotech Mutual Funds for 2017

                          Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance

                            Is the Options Market Predicting a Spike in Gilead Sciences (GILD) Stock?

                            Investors in Gilead Sciences Inc. (GILD) need to pay close attention to the stock based on moves in the options market lately.

                              Gilead (GILD) HBV Drug Vemlidy Receives European Approval

                              Gilead Sciences (GILD) gained EU approval for Vemlidy for the treatment of chronic HBV infection.

                                Madeleine Johnson headshot

                                Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment

                                After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.

                                  The Zacks Analyst Blog Highlights: Gilead Sciences, Pepsi, United Parcel Services, Twitter and Stanley Black & Decker

                                  The Zacks Analyst Blog Highlights: Gilead Sciences, Pepsi, United Parcel Services, Twitter and Stanley Black & Decker

                                    Sheraz Mian headshot

                                    Top Research Reports for Pepsi, UPS & Gilead Sciences

                                    Today's Research Daily features new research reports on 16 major stocks, including Gilead Sciences (GILD), Pepsi (PEP) and United Parcel Services (UPS).

                                      Stock Market News for January 04, 2017

                                      Benchmarks finished in the green on the first trading day of 2017 as investors strived to make up for losses suffered during the last few sessions of profit booking

                                        United Therapeutics' PAH Suite Bodes Well, Competition Rife

                                        On Dec 29, 2016, we issued an updated report on United Therapeutics Corporation (UTHR).

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug

                                          Biotech stocks like Conatus (CNAT) and Clovis reported positive developments this week with one company signing a deal and the other getting accelerated FDA approval for its cancer treatment.

                                            Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls

                                            Gilead (GILD) has been ordered to pay $2.5 billion in royalties to Merck (MRK) in the largest patent infringement dispute in the history of the U.S.

                                              Arpita Dutt headshot

                                              Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data

                                              Several companies presented data this week with companies like Achaogen (AKAO) soaring while others like Ophthotech plunged.

                                                The Zacks Analyst Blog Highlights: Gilead Sciences, Medtronic, NVIDIA, Accenture and Simon Property

                                                The Zacks Analyst Blog Highlights: Gilead Sciences, Medtronic, NVIDIA, Accenture and Simon Property

                                                  Sheraz Mian headshot

                                                  Top Research Reports for NVIDIA, Medtronic & Gilead Sciences

                                                  Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), Medtronic (MDT) and NVIDIA (NVDA).